Senator Introduces Legislation to Overhaul GRAS Provision

“Generally Recognized as Safe” sounds comforting, almost cozy. It sounds like the regulatory equivalent of chicken soup. But in Washington, the GRAS provision has become one of the hottest food-policy arguments on the menu. And now Senator Roger Marshall’s Better Food Disclosure Act of 2025 is trying to turn that argument into law.

The bill takes aim at one of the most controversial features of U.S. food law: the fact that some substances can enter the food supply without going through the same premarket approval process required for traditional food additives. Supporters call Marshall’s proposal a long-overdue transparency upgrade. Critics say it is a meaningful start, but not the full kitchen renovation needed to fix a system they believe has been running on outdated assumptions, thin oversight, and far too much trust in companies to grade their own homework.

Either way, the legislation lands at a moment when the GRAS debate is no longer a niche policy scuffle for regulatory lawyers and food chemists. States are moving faster. The FDA has started flexing more post-market muscle. Consumers are reading labels like mini detectives. And food companies are getting the message that “because we’ve always done it this way” is no longer a winning compliance strategy.

What the GRAS Provision Actually Does

Under federal law, a substance intentionally added to food is generally considered a food additive, which means it usually needs FDA premarket review and approval. But there is a major exception: if qualified experts generally recognize the substance as safe under its intended conditions of use, it can qualify as GRAS instead.

That exception was originally meant to make practical sense. Congress did not want the FDA to spend its days holding emergency hearings on vinegar, flour, salt, or baking soda. If an ingredient had a long history of safe use or well-established scientific support, it did not need the same full petition process as a brand-new additive.

In theory, that still sounds reasonable. In practice, however, the fight begins over what counts as “generally recognized,” who the experts are, how independent they are, and whether the FDA ever gets a real chance to examine the evidence before the ingredient shows up in a protein bar, energy drink, dairy alternative, or shelf-stable snack with a label longer than a mortgage agreement.

The FDA says GRAS conclusions based on scientific procedures should rest on the same quantity and quality of evidence needed for a food additive approval. The catch is that the FDA’s GRAS notification program has been voluntary. A company can submit a GRAS notice to the agency, but it has not always been required to do so. That is the crack in the wall that reformers have spent years calling a loophole.

Why Senator Marshall’s Bill Matters

Marshall’s bill is designed to change that basic dynamic. Instead of leaving GRAS notification as an optional step, the legislation would create a mandatory reporting framework tied to a publicly accessible FDA list of GRAS substances.

A public list instead of a wink and a nod

The bill says that, beginning two years after enactment, a GRAS substance would be deemed unsafe for a particular use unless it is either included on the FDA’s public list or currently under FDA review. That is a major structural shift. Today, the system can allow a company to make a GRAS determination that never reaches the agency’s desk. Under Marshall’s proposal, the ingredient would need to show up in a federal listing system.

Deadlines for old and new ingredients

The legislation draws a line between substances already in the marketplace and substances that would be used after the law takes effect. Existing GRAS substances already used in interstate commerce would have to be reported within two years of enactment. New GRAS substances would have to be reported at least 120 days before their first use in food sold in interstate commerce.

That is not a small tweak. It would create a paper trail where, in many cases, consumers and regulators have long complained there was too little visibility.

A 180-day FDA response window

Once a notice is filed, the FDA would have 180 days to add the substance to the public list or make a preliminary determination to exclude it. If the agency does not act within that window, the substance would be deemed added to the list. That automatic-listing feature is one of the most important and most debated parts of the bill.

Supporters may see it as a way to force the agency to move and avoid bureaucratic limbo. Skeptics may see it as a pressure point that rewards FDA delay with market access, which is not exactly the kind of sentence that makes public-health advocates want to throw confetti.

Post-market review with citizen and state input

The measure also expands the post-market review conversation. If the FDA receives a citizen petition or a notice from a state government official raising safety concerns about a food additive, color additive, or listed GRAS substance, the agency could reevaluate it. If a listed GRAS substance no longer passes muster, the FDA could remove it from the list and reclassify it as a food additive subject to stricter requirements.

That matters because the bill is not only about what gets in the door. It is also about what happens after the ingredient is already in the pantry, on the shelf, and in the lunchbox.

Why the Current GRAS System Has Taken So Much Heat

The modern backlash did not appear out of thin air. It has been building for years through watchdog reports, consumer advocacy campaigns, academic criticism, and government audits.

One of the most frequently cited warnings came from the U.S. Government Accountability Office. In a 2010 report, GAO said FDA oversight did not ensure the safety of all new GRAS determinations because the agency only reviews the ones companies voluntarily submit. GAO also said FDA generally does not have information about other GRAS determinations companies have made on their own. That finding has haunted the debate ever since.

GAO later continued raising concerns about FDA’s broader post-market review limitations for substances used in food packaging and manufacturing, noting that the agency lacked some of the data and legal tools needed for a more systematic, risk-informed process. Translation: the government’s own auditors have repeatedly said the agency’s visibility into food chemicals has gaps, and those gaps are not tiny.

Advocacy groups such as the Center for Science in the Public Interest and Environmental Working Group have used even blunter language, often calling the current framework the “GRAS loophole” or “secret GRAS.” Their argument is simple: if a company can make a safety conclusion without mandatory FDA review and the public never sees the full underlying record, transparency is weak by design, not by accident.

To be fair, defenders of the existing framework note that many GRAS substances are widely used and uncontroversial, and that innovation in food ingredients can move faster when the system does not force every low-risk substance through a full petition process. But even many people who do not want to kill GRAS altogether are increasingly open to more disclosure, stronger conflict-of-interest guardrails, and better post-market reassessment.

Why Congress Is Suddenly So Interested

Marshall’s bill did not appear in a vacuum. It arrived during a period of broader momentum around food chemical scrutiny.

California helped change the political temperature in 2023 when Governor Gavin Newsom signed AB 418, a law banning four additives in food sold in the state beginning January 1, 2027: brominated vegetable oil, potassium bromate, propylparaben, and Red Dye No. 3. The message was unmistakable: if Washington moves slowly, states may stop waiting.

By 2025, state-level activity had accelerated further. Marshall’s office said 108 bills across 17 states had been introduced during the 2025 legislative session on issues tied to ingredients, nutrition, and ultra-processed foods, with seven bills enacted in five states. That is not just policy chatter. That is a flashing neon sign telling Congress that the federal government risks losing control of the national standard.

The FDA, for its part, has also become more active. In July 2024, it revoked the authorization allowing brominated vegetable oil in food after concluding there was no longer a basis to consider that use safe. In January 2025, it revoked the authorization for Red No. 3 in food and ingested drugs. In May 2025, the agency announced a more systematic post-market chemical review program and identified chemicals such as BHT, BHA, and azodicarbonamide for closer scrutiny, while speeding work on phthalates, propylparaben, and titanium dioxide.

That matters politically because once the FDA starts acting, lawmakers start smelling opportunity. Nobody in Washington wants to be the one defending the regulatory status quo when headlines keep featuring dyes, preservatives, and “chemicals in food” in the same sentence.

Is This Really an Overhaul, or Just a Cleanup Job?

The honest answer is: it depends on what you think the problem is.

If you believe the main problem is secrecy, Marshall’s bill is a serious reform. A mandatory notification system, a public FDA list, and a process for post-market petitions would make the GRAS landscape more transparent than it is now. Consumers, state officials, researchers, and competitors would at least be able to see much more clearly what substances are being claimed as GRAS and for what uses.

If you believe the core problem is that companies should never be able to introduce novel food chemicals without affirmative FDA approval, then Marshall’s bill may look incomplete. It does not abolish GRAS. It does not convert every new GRAS claim into a classic food additive petition. And because the bill allows a substance to be deemed listed if FDA misses the 180-day window, some critics will argue it still leaves too much room for passive approval.

That tension becomes even clearer when you compare Marshall’s measure with more aggressive proposals such as the Ensuring Safe and Toxic-Free Foods Act of 2025, introduced by Senators Edward Markey and Cory Booker. That proposal goes further by pushing for stronger public disclosure, more detailed safety submissions, conflict-of-interest standards for experts, and tighter limits on what can qualify as GRAS in the first place.

So yes, Marshall’s bill would overhaul part of the GRAS system. But it would overhaul the transparency and listing architecture more than the underlying legal concept. It is not a demolition crew. It is a major remodel with some walls left standing.

What the Bill Could Mean for Consumers and the Food Industry

For consumers, the biggest potential gain is visibility. Food regulation is often maddeningly technical, but transparency still matters. Even when the average shopper is not reading Federal Register notices for fun and let us hope they have more exciting hobbies stronger disclosure can improve accountability, support independent research, and reduce the sense that ingredient safety is being managed behind a curtain.

For food companies, the bill could mean more paperwork, more legal review, more scientific substantiation, and more questions about timing. Businesses using older GRAS substances would need to prepare notices. Companies introducing new substances would need to think earlier about regulatory strategy. That may slow some product launches, but it could also reduce the reputational chaos that comes when an ingredient suddenly becomes the villain of the week.

For the FDA, the bill would create more responsibility and, likely, more pressure for resources. A mandatory system is only as strong as the agency administering it. If Congress wants the FDA to review more notices, maintain a public list, evaluate petitions, and conduct more post-market reassessments, it will also need to care about staffing, scientific capacity, and turnaround time. A tougher law with a thinly resourced agency is how you end up promising filet mignon and serving regulatory crackers.

Experiences From the Front Lines of the GRAS Debate

The most interesting part of the GRAS fight is not the acronym itself. It is the human experience around it. And that experience has changed dramatically over the past few years.

For many consumers, the experience starts with confusion. They stand in a grocery aisle looking at a package that says “natural,” “clean,” or “made with simple ingredients,” and then flip it over to find a label full of words that sound like either chemistry homework or a very ambitious robot wrote them. Most shoppers are not asking for a Ph.D. in toxicology. They are asking a simpler question: why is this in my food, and who checked it? The GRAS debate became politically powerful because it speaks directly to that ordinary, everyday frustration.

Parents have had a particularly vivid version of that experience. The conversation around synthetic dyes, hyperactivity, and children’s foods has turned school snacks and brightly colored treats into miniature culture-war battlegrounds. Whether every concern is equally supported by the science is a separate question. What matters politically is that families increasingly want the government to explain why one state is restricting an ingredient while another still allows it. That patchwork creates a feeling that safety rules are negotiable, and consumers tend to hate that almost as much as they hate surprise fees.

Smaller food companies have their own version of the story. For some, the current GRAS system offers flexibility and speed. A company working on fermentation-derived ingredients, alternative proteins, or reformulated preservatives may prefer a pathway that is faster than a full food additive petition. But speed can also become a trap. An ingredient that clears a product launch more quickly can later become a regulatory headache if public scrutiny grows, states adopt new rules, or large retailers get nervous and demand reformulation. Many companies are learning that a faster route to market is not always the same thing as a safer route to long-term brand stability.

State lawmakers and attorneys general are experiencing the issue from yet another angle. Their frustration often stems from the perception that federal action has been too slow, too opaque, or too reactive. Once states begin stepping in, they are no longer just filling a policy gap. They are sending a message to Washington that consumer trust is becoming a state-level issue because the federal government has not fully settled it. That helps explain why the GRAS debate now feels bigger than a narrow food-law dispute. It has become a test of who gets to define precaution, transparency, and modern food safety in the United States.

Then there is the FDA experience, which is less dramatic but no less important. Agency scientists and regulators are being asked to govern a food system that is more complex, more global, and more chemically sophisticated than the one Congress was thinking about in 1958. They are also working in a political environment where every decision can trigger criticism from industry, consumer advocates, states, lawmakers, or all four before lunch. That reality helps explain why recent FDA actions on BVO, Red No. 3, synthetic dyes, and post-market review have drawn so much attention. They are signals that the agency understands public patience has gotten thinner than a rice cracker.

All of those experiences are converging now. The shopper wants clarity. The brand wants predictability. The state wants action. The FDA wants workable authority. Congress wants credit. And the GRAS system, once treated like a technical side street of food law, is now standing in the middle of a very busy intersection with traffic coming from every direction.

Final Take

Senator Marshall’s legislation is significant because it acknowledges something Washington has been slow to admit: the old GRAS framework no longer inspires much public confidence when ingredients can be used in food without mandatory FDA notification. By requiring reporting, building a public list, and expanding pathways for post-market review, the bill would make the system more visible and more accountable than it is today.

But visibility is not the same thing as full premarket approval. That is why this debate is not going away. Marshall’s proposal may be the beginning of a federal reset, not the end of it. And if Congress truly wants to overhaul the GRAS provision in a way that satisfies both science and public trust, the next round of legislation may need to answer a harder question: should food companies be allowed to decide first and tell the FDA later, or should the FDA be back in the driver’s seat before the ingredient ever reaches the shelf?

In the world of food regulation, that is no longer a wonky side question. It is the whole recipe.